ACADEMIA

• Academic Societies Urge COVID-19 Vaccinations, Deny Kostaive “Shedding”
  October 22, 2024

• Non-HCPs Have Higher Expectations of Alzheimer’s Drugs than Specialists: Poll
  October 7, 2024

• Pharmacies, Hospitals Scrambling to Address New LLP Coverage Rule, Concerns Swirl Around Misuse
  October 1, 2024

• KOL Calls for Public Support for Truvada’s PrEP Use against HIV
  September 26, 2024

• Early Use of High-Dose Mecobalamin Extends Survival in ALS: IIT Data
  September 20, 2024

• NCC, Eisai Confirm Tumor Shrinkage with E7820 Using J-PDX Models
  September 17, 2024

• Japan Study Finds No Evidence of Increased Cancer Risk for Sitagliptin
  September 3, 2024

• A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
  August 28, 2024

• As Kisunla Approval Nears, Japanese Alzheimer’s KOL Hails Increase in Options
  August 9, 2024

• Japan’s Antibiotic Use Up 22.3% in 2023 after COVID Restrictions Lifted
  August 7, 2024

• NCC Out-Licenses UPenn-Partnered Cell Therapy to Spinout Company
  July 12, 2024

• 8.5% of Long-COVID Patients Still Seriously Affected after 6 Months: Survey
  July 4, 2024

• Academic Society Frets Availability of 1st-Gen Oral Cephems amid Choseido Halt
  June 24, 2024

• MHLW-Funded Study Group Designing New Care Delivery Model for Alzheimer’s
  June 14, 2024

• Leukemia Drug Slows ALS Progression in Japan Clinical Trial
  June 13, 2024

• Akira Endo, Who Pioneered Discovery of Statins, Dies at 90
  June 12, 2024

• Single-Injection Beyfortus Will Reduce Burdens on Parents and Children: Experts
  June 10, 2024

• Researchers Crafting Japan’s 1st Guidelines for ALS Trials, Eye FY2026 Completion
  May 14, 2024

• Japan to Forge National Registry for Leqembi, Test Genes to Predict Side Effects
  May 8, 2024

• Lecanemab Combo Trial Launched in Japan for Familial Alzheimer’s
  March 18, 2024

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »